Treatment progress of relapsed/refractory follicular lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 79-81, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-988956
ABSTRACT
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. The outcome of relapsed/refractory FL patients after multi-therapy is poor. The 64th American Society of Hematology annual meeting in 2022 announced the latest updates on relapsed/refractory FL, including targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell. This review provides an overview of these updates.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS